Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax (2022)
- Authors:
- USP affiliated authors: PONTES, LORENA LÔBO DE FIGUEIREDO - FMRP ; REGO, EDUARDO MAGALHÃES - FM ; MACHADO NETO, JOÃO AGOSTINHO - ICB ; LIMA, KELI CRISTINA DE - FM ; VICARI, HUGO PASSOS - ICB ; SILVA, JEAN CARLOS LIPRERI DA - ICB
- Unidades: FMRP; FM; ICB
- DOI: 10.1016/j.htct.2021.01.004
- Subjects: FARMACOLOGIA; LEUCEMIA MIELOIDE AGUDA; APOPTOSE; MEDICAMENTO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: São José do Rio Preto
- Date published: 2022
- Source:
- Título: Hematology, Transfusion and Cell Therapy
- ISSN: 2531-1387
- Volume/Número/Paginação/Ano: v. 44, n. 1, p. 124-127, 2022
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by-nc-nd
-
ABNT
LIMA, Keli Cristina de et al. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2021.01.004. Acesso em: 03 nov. 2024. , 2022 -
APA
Lima, K. C. de, Vicari, H. P., Carlos, J. A. E. G., Silva, J. C. L. da, Pontes, L. L. de F., Rego, E. M., & Machado Neto, J. A. (2022). Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.htct.2021.01.004 -
NLM
Lima KC de, Vicari HP, Carlos JAEG, Silva JCL da, Pontes LL de F, Rego EM, Machado Neto JA. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 1): 124-127.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/j.htct.2021.01.004 -
Vancouver
Lima KC de, Vicari HP, Carlos JAEG, Silva JCL da, Pontes LL de F, Rego EM, Machado Neto JA. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 1): 124-127.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1016/j.htct.2021.01.004 - Ezrin is highly expressed and a druggable target in chronic lymphocytic leukemia
- Cellular and molecular effects of Eribulin in preclinical models of hematologic neoplasms
- ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia
- Comprehensive analysis of the HCK gene in myeloid neoplasms: insights into biological functions, prognosis, and response to antineoplastic agents
- STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells
- CDC7 (cell division cycle 7)
- Synthetic cyclopenta[b]indoles exhibit antineoplastic activity by targeting microtubule dynamics in acute myeloid leukemia cells
- Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms
- Transcriptomics analysis identified ezrin as a potential druggable target in cervical and gastric cancer cells
- Exploring redox vulnerabilities in JAK2V617F-positive cellular models
Informações sobre o DOI: 10.1016/j.htct.2021.01.004 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 | Obatoclax_reduces_cell_vi... | Direct link | |
| 003025145.pdf | Direct link |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
